{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:23:43Z","timestamp":1791660223822,"version":"4.3.4"},"reference-count":211,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007088","name":"Jagiellonian University","doi-asserted-by":"publisher","award":["N41\/DBS\/001247"],"award-info":[{"award-number":["N41\/DBS\/001247"]}],"id":[{"id":"10.13039\/501100007088","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Aging is a key risk factor for atherosclerosis progression that is associated with increased incidence of ischemic events in supplied organs, including stroke, coronary events, limb ischemia, or renal failure. Cardiovascular disease is the leading cause of death and major disability in adults \u2265 75 years of age. Atherosclerotic occlusive disease affects everyday activity, quality of life, and it is associated with reduced life expectancy. As most multicenter randomized trials exclude elderly and very elderly patients, particularly those with severe comorbidities, physical or cognitive dysfunctions, frailty, or residence in a nursing home, there is insufficient data on the management of older patients presenting with atherosclerotic lesions outside coronary territory. This results in serious critical gaps in knowledge and a lack of guidance on the appropriate medical treatment. In addition, due to a variety of severe comorbidities in the elderly, the average daily number of pills taken by octogenarians exceeds nine. Polypharmacy frequently results in drug therapy problems related to interactions, drug toxicity, falls with injury, delirium, and non-adherence. Therefore, we have attempted to gather data on the medical treatment in patients with extra-cardiac atherosclerotic lesions indicating where there is some evidence of the management in elderly patients and where there are gaps in evidence-based medicine. Public PubMed databases were searched to review existing evidence on the effectiveness of lipid-lowering, antithrombotic, and new glucose-lowering medications in patients with extra-cardiac atherosclerotic occlusive disease.<\/jats:p>","DOI":"10.3390\/jcm13051508","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T04:03:50Z","timestamp":1709697830000},"page":"1508","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients\u2014A Review PART II\u2014Pharmacological Approach for Management of Elderly Patients with Peripheral Atherosclerotic Lesions outside Coronary Territory"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4067-2229","authenticated-orcid":false,"given":"Marcin","family":"Piechocki","sequence":"first","affiliation":[{"name":"Department of Vascular and Endovascular Surgery, The St. John Paul II Hospital, Pr\u0105dnicka 80, 31-202 Krakow, Poland"},{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, Jagiellonian University Medical College, \u015bw. Anny 12, 31-007 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Przew\u0142ocki","sequence":"additional","affiliation":[{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, Jagiellonian University Medical College, \u015bw. Anny 12, 31-007 Krakow, Poland"},{"name":"Department of Interventional Cardiology, The St. John Paul II Hospital, Pr\u0105dnicka 80, 31-202 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Pieni\u0105\u017cek","sequence":"additional","affiliation":[{"name":"Department of Vascular and Endovascular Surgery, The St. John Paul II Hospital, Pr\u0105dnicka 80, 31-202 Krakow, Poland"},{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, Jagiellonian University Medical College, \u015bw. Anny 12, 31-007 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Trystu\u0142a","sequence":"additional","affiliation":[{"name":"Department of Vascular and Endovascular Surgery, The St. John Paul II Hospital, Pr\u0105dnicka 80, 31-202 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Podolec","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, The St. John Paul II Hospital, Pr\u0105dnicka 80, 31-202 Krakow, Poland"},{"name":"Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College, \u015bw. Anny 12, 31-007 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-7840","authenticated-orcid":false,"given":"Anna","family":"Kab\u0142ak-Ziembicka","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College, \u015bw. Anny 12, 31-007 Krakow, Poland"},{"name":"Noninvasive Cardiovascular Laboratory, The St. John Paul II Hospital, Pr\u0105dnicka 80, 31-202 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990\u20132019: Update from the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.31128\/AJGP-11-19-5160","article-title":"Peripheral artery disease in the lower limbs: The importance of secondary risk prevention for improved long-term prognosis","volume":"49","author":"Aitken","year":"2022","journal-title":"Am. J. Gen. Pract."},{"key":"ref_3","first-page":"e20210251","article-title":"The Influence of Primary Atherosclerotic Diseases on the Occurrence of Secondary Disease","volume":"36","author":"Picoli","year":"2022","journal-title":"Int. J. Cardiovasc. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e025504","DOI":"10.1161\/JAHA.122.025504","article-title":"Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease","volume":"11","author":"Szarek","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12933-016-0360-2","article-title":"The coexistence of carotid and lower extremity atherosclerosis further increases cardio-cerebrovascular risk in type 2 diabetes","volume":"15","author":"Li","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart Disease and Stroke Statistics-2022 Update: A Report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Cartland, S.P., Stanley, C.P., Bursill, C., Passam, F., Figtree, G.A., Patel, S., Loa, J., Golledge, J., Robinson, D.A., and Aitken, S.J. (2023). Sex, Endothelial Cell Functions, and Peripheral Artery Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242417439"},{"key":"ref_9","unstructured":"(2020, January 16). Eurostat Data Browser. Available online: https:\/\/ec.europa.eu\/eurostat\/databrowser\/bookmark\/155f95f1-3158-4241-b034-f0c608e207f9?lang=en&page=time:2022."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3399\/bjgp17X693221","article-title":"Future Care for Older People in General Practice: Paradigm Shifts Are Needed","volume":"67","author":"Schuurmans","year":"2017","journal-title":"Br. J. Gen. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"afab282","DOI":"10.1093\/ageing\/afab282","article-title":"Clinical trials in older people","volume":"51","author":"Pitkala","year":"2022","journal-title":"Age Ageing"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"818875","DOI":"10.3389\/fphar.2022.818875","article-title":"Medication Use and Costs Among Older Adults Aged 90 Years and Older in Italy","volume":"13","author":"Zazzara","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_13","first-page":"16347","article-title":"Prevalence, Predisposing Factors and Strategies to Reduce Polypharmacy among Older Patients in Poland","volume":"132","author":"Grodzicki","year":"2022","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Davies, L.E., Kingston, A., Todd, A., and Hanratty, B. (2021). Characterising Polypharmacy in the Very Old: Findings from the Newcastle 85+ Study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0245648"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Konrat, C., Boutron, I., Trinquart, L., Auleley, G.-R., Ricordeau, P., and Ravaud, P. (2012). Underrepresentation of Elderly People in Randomised Controlled Trials. The Example of Trials of 4 Widely Prescribed Drugs. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033559"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in Collaboration with the European Society for Vascular Surgery (ESVS): Document Covering Atherosclerotic Disease of Extracranial Carotid and Vertebral, Mesenteric, Renal, Upper and Lower Extremity Arteries. Endorsed by: The European Stroke Organization (ESO). The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS)","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/01.cir.0000436752.99896.22","article-title":"Secondary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults: A Scientific Statement from the American Heart Association","volume":"128","author":"Fleg","year":"2013","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"868370","DOI":"10.3389\/fcvm.2022.868370","article-title":"Burden of Peripheral Artery Disease and Its Attributable Risk Factors in 204 Countries and Territories From 1990 to 2019","volume":"9","author":"Lin","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Park, Y.S., Ryu, G.W., and Choi, M. (2022). Multiple Metabolic Comorbidities and Their Consequences among Patients with Peripheral Arterial Disease. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0268201"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Klimontov, V.V., Koroleva, E.A., Khapaev, R.S., Korbut, A.I., and Lykov, A.P. (2021). Carotid Artery Disease in Subjects with Type 2 Diabetes: Risk Factors and Biomarkers. J. Clin. Med., 11.","DOI":"10.3390\/jcm11010072"},{"key":"ref_22","first-page":"276","article-title":"Increased risk profile in the treatment of patients with symptomatic degenerative aortic valve stenosis over the last 10 years","volume":"14","author":"Baran","year":"2018","journal-title":"Adv. Interv. Cardiol."},{"key":"ref_23","first-page":"i","article-title":"Polypharmacy: A global risk factor for elderly people","volume":"6","author":"Dagli","year":"2014","journal-title":"J. Int. Oral Health"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Alsufyani, M.H., Alghoribi, M.H., Bin Salman, T.O., Alrabie, A.F., Alotaibi, I.S., Kharbosh, A.M., Alsheikh, M.Y., Alshahrani, A.M., and Fathelrahman, A.I. (2023). Generic Substitutions and Therapeutic Interchanges in Hospital Pharmacies: A Qualitative Study from Western Saudi Arabia. Healthcare, 11.","DOI":"10.3390\/healthcare11131893"},{"key":"ref_25","first-page":"808","article-title":"Prospective Study on the Prognostic Value of Repeated Carotid Intima-Media Thickness Assessment in Patients with Coronary and Extra Coronary Steno-Occlusive Arterial Disease","volume":"129","author":"Gacon","year":"2019","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1161\/CIRCULATIONAHA.120.046361","article-title":"Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100,667 Patients","volume":"142","author":"Willeit","year":"2020","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100371","DOI":"10.1016\/j.ajpc.2022.100371","article-title":"There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness","volume":"12","author":"Makover","year":"2022","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jacc.2021.10.035","article-title":"Coronary Atherosclerotic Plaque Regression: JACC State-of-the-Art Review","volume":"79","author":"Dawson","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kab\u0142ak-Ziembicka, A. (2022). Improving Cardiovascular Outcomes: The Era of Personalized Therapy in Atherosclerosis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11113077"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Biccir\u00e8, F.G., Gatto, L., La Porta, Y., Pignatelli, P., Prati, F., and Pastori, D. (2023). Effects of Lipid Lowering Therapies on Vulnerable Plaque Features: An Updated Narrative Review of the Literature. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10060260"},{"key":"ref_31","first-page":"74","article-title":"The Role of Serial Carotid Intima-Media Thickness Assessment as a Surrogate Marker of Atherosclerosis Control in Patients with Recent Myocardial Infarction","volume":"15","author":"Przewlocki","year":"2019","journal-title":"Post\u0119py Kardiol. Interw."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/tomography8010044","article-title":"Rapid Regression of Carotid Artery Stenosis Shortly after Intensive Medical Therapy","volume":"8","author":"Park","year":"2022","journal-title":"Tomography"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3949\/ccjm.73.10.937","article-title":"Coronary atherosclerosis can regress with very intensive statin therapy","volume":"73","author":"Sipahi","year":"2006","journal-title":"Clevel. Clin. J. Med."},{"key":"ref_34","first-page":"8887248","article-title":"The Role of Angiotensin Antagonism in Coronary Plaque Regression: Insights from the Glagovian Model","volume":"2021","author":"Alkatiri","year":"2021","journal-title":"Int. J. Vasc. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Quan, W., Han, H., Liu, L., Sun, Y., Zhu, Z., Du, R., Zhu, T., and Zhang, R. (2023). Influence of LDL-Cholesterol Lowering on Coronary Plaque Progression of Non-Target Lesions in Patients Undergoing Percutaneous Coronary Intervention: Findings from a Retrospective Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12030785"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.7863\/ultra.15.10042","article-title":"Multiterritory Atherosclerosis and Carotid Intima-Media Thickness as Cardiovascular Risk Predictors after Percutaneous Angioplasty of Symptomatic Subclavian Artery Stenosis","volume":"35","author":"Wrotniak","year":"2016","journal-title":"J. Ultrasound Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"818537","DOI":"10.3389\/fendo.2022.818537","article-title":"Effects of Antidiabetic Drugs on Endothelial Function in Patients with Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1041400","DOI":"10.3389\/fphar.2022.1041400","article-title":"Effect of Aspirin in Patients with Established Asymptomatic Carotid Atherosclerosis: A Systematic Review and Meta-Analysis","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Cui, Y., Zhu, Q., Hao, H., Flaker, G.C., and Liu, Z. (2023). N-Acetylcysteine and Atherosclerosis: Promises and Challenges. Antioxidants, 12.","DOI":"10.3390\/antiox12122073"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Orellana-Urz\u00faa, S., Briones-Valdivieso, C., Chichiarelli, S., Saso, L., and Rodrigo, R. (2023). Potential Role of Natural Antioxidants in Countering Reperfusion Injury in Acute Myocardial Infarction and Ischemic Stroke. Antioxidants, 12.","DOI":"10.3390\/antiox12091760"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Howes, L.G., Unni, T., Hamza, A., Howes, J.B., and Jayasinghe, R. (2023). Reduction in Arterial Stiffness Index (SI) in Response to Combination Antioxidant Therapy. J. Clin. Med., 12.","DOI":"10.20944\/preprints202308.1255.v1"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Dziedzic, E.A., Grant, W.B., Sowi\u0144ska, I., D\u0105browski, M., and Jankowski, P. (2022). Small Differences in Vitamin D Levels between Male Cardiac Patients in Different Stages of Coronary Artery Disease. J. Clin. Med., 11.","DOI":"10.3390\/jcm11030779"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Wang, J., Zhou, J.J., Robertson, G.R., and Lee, V.W. (2018). Vitamin D in Vascular Calcification: A Double-Edged Sword?. Nutrients, 10.","DOI":"10.3390\/nu10050652"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Zhang, H., Wang, L., Peng, F., Wang, X., and Gong, H. (2020). L-Arginine Ameliorates High-Fat Diet-Induced Atherosclerosis by Downregulating MiR-221. BioMed Res. Int., 2020.","DOI":"10.1155\/2020\/4291327"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fnagi.2018.00418","article-title":"Nitrendipine and Dementia: Forgotten Positive Facts?","volume":"10","author":"Novotny","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1001\/archinte.162.18.2046","article-title":"The Prevention of Dementia with Antihypertensive Treatment: New Evidence from the Systolic Hypertension in Europe (Syst-Eur) Study","volume":"162","author":"Forette","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"M172","DOI":"10.1093\/gerona\/59.2.M172","article-title":"Management of Peripheral Arterial Disease of the Lower Extremities in Elderly Patients","volume":"59","author":"Aronow","year":"2004","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_48","unstructured":"Aronow, W.S. (2024, February 22). Treatment of Peripheral Arterial Disease in the Elderly Person. Ann. Long-Term Care 2005. Available online: https:\/\/www.hmpgloballearningnetwork.com\/site\/altc\/article\/4644."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2147\/CIA.S2412","article-title":"Peripheral Arterial Disease in the Elderly","volume":"2","author":"Aronow","year":"2008","journal-title":"Clin. Interv. Aging"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Martelli, E., Enea, I., Zamboni, M., Federici, M., Bracale, U.M., Sangiorgi, G., Martelli, A.R., Messina, T., and Settembrini, A.M. (2023). Focus on the Most Common Paucisymptomatic Vasculopathic Population, from Diagnosis to Secondary Prevention of Complications. Diagnostics, 13.","DOI":"10.20944\/preprints202305.0209.v1"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.jacc.2016.03.004","article-title":"Knowledge Gaps in Cardiovascular Care of the Older Adult Population: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society","volume":"67","author":"Rich","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3949\/ccjm.84a.15114","article-title":"Severely Frail Elderly Patients Do Not Need Lipid-Lowering Drugs","volume":"84","author":"Mallery","year":"2017","journal-title":"Clevel. Clin. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e002333","DOI":"10.1136\/bmjopen-2012-002333","article-title":"Statin Use and Clinical Outcomes in Older Men: A Prospective Population-Based Study","volume":"3","author":"Gnjidic","year":"2013","journal-title":"BMJ Open"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamainternmed.2017.1442","article-title":"Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial","volume":"177","author":"Han","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamainternmed.2013.6184","article-title":"Statins and musculoskeletal conditions, arthropathies, and injuries","volume":"173","author":"Mansi","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/HCO.0000000000001003","article-title":"Primary prevention statin therapy in older adults","volume":"38","author":"Nanna","year":"2023","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet, 380, 581\u2013590.","DOI":"10.1016\/S0140-6736(12)60367-5"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"k3359","DOI":"10.1136\/bmj.k3359","article-title":"Statins for Primary Prevention of Cardiovascular Events and Mortality in Old and Very Old Adults with and without Type 2 Diabetes: Retrospective Cohort Study","volume":"362","author":"Ramos","year":"2018","journal-title":"BMJ"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2020.7848","article-title":"Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older","volume":"324","author":"Orkaby","year":"2020","journal-title":"JAMA"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Mueller, L., Engelbertz, C., Reinecke, H., Freisinger, E., Malyar, N.M., Meyborg, M., Brix, T.J., Varghese, J., and Gebauer, K. (2022). Secondary Prevention in Lower Extremity Artery Disease Patients: Lipid-Lowering Therapy and Long-Term Guideline Adherence. J. Clin. Med., 11.","DOI":"10.3390\/jcm11226838"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/jgs.16975","article-title":"Statin Use in Older Adults with Stable Atherosclerotic Cardiovascular Disease","volume":"69","author":"Chung","year":"2021","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jacc.2007.06.063","article-title":"Statins for Secondary Prevention in Elderly Patients: A Hierarchical Bayesian Meta-Analysis","volume":"51","author":"Afilalo","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1212\/01.wnl.0000327339.55844.1a","article-title":"Effect of Atorvastatin in Elderly Patients with a Recent Stroke or Transient Ischemic Attack","volume":"72","author":"Chaturvedi","year":"2009","journal-title":"Neurology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1161\/STROKEAHA.108.516450","article-title":"Atorvastatin Reduces the Risk of Cardiovascular Events in Patients with Carotid Atherosclerosis: A Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial","volume":"39","author":"Sillesen","year":"2008","journal-title":"Stroke"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejvs.2018.09.018","article-title":"Optimal Antiplatelet Therapy in Moderate to Severe Asymptomatic and Symptomatic Carotid Stenosis: A Comprehensive Review of the Literature","volume":"57","author":"Stephen","year":"2019","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jacc.2014.12.045","article-title":"How Recent Data Have Impacted the Treatment of Internal Carotid Artery Stenosis","volume":"65","author":"Chaturvedi","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1161\/STROKEAHA.113.001576","article-title":"Reduction in Early Stroke Risk in Carotid Stenosis with Transient Ischemic Attack Associated with Statin Treatment","volume":"44","author":"Merwick","year":"2013","journal-title":"Stroke"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.12.030","article-title":"Association Between Total Cholesterol and 5 Year Mortality in Patients with Carotid Artery Stenosis and Poststroke Functional Dependence","volume":"28","author":"Lung","year":"2019","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"c35","DOI":"10.1159\/000107552","article-title":"The Effects of Statins on the Progression of Atherosclerotic Renovascular Disease","volume":"107","author":"Cheung","year":"2007","journal-title":"Nephron Clin. Pract."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/eurheartj\/ehi304","article-title":"Atherosclerotic Renovascular Disease in Chronic Heart Failure: Should We Intervene?","volume":"26","author":"Nikitin","year":"2005","journal-title":"Eur. Heart J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ccd.21121","article-title":"Factors affecting long-term survival following renal artery stenting","volume":"69","author":"Bates","year":"2007","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/eurheartj\/ehq452","article-title":"Statins and Renovascular Disease in the Elderly: A Population-Based Cohort Study","volume":"32","author":"Hackam","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1024\/0301-1526\/a001012","article-title":"Statins and Statin Intensity in Peripheral Artery Disease","volume":"51","author":"Sagris","year":"2022","journal-title":"Vasa"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jvs.2017.09.022","article-title":"The Association of Statin Therapy with the Primary Patency of Femoral and Popliteal Artery Stents","volume":"67","author":"Teixeira","year":"2018","journal-title":"J. Vasc. Surg."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jvs.2003.08.030","article-title":"Patients Undergoing Infrainguinal Bypass to Treat Atherosclerotic Vascular Disease Are Underprescribed Cardioprotective Medications: Effect on Graft Patency, Limb Salvage, and Mortality","volume":"39","author":"Henke","year":"2004","journal-title":"J. Vasc. Surg."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0002-9149(02)02616-4","article-title":"Frequency of New Coronary Events in Older Persons with Peripheral Arterial Disease and Serum Low-Density Lipoprotein Cholesterol > or = 125 Mg\/Dl Treated with Statins versus No Lipid-Lowering Drug","volume":"90","author":"Aronow","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5551\/jat.49767","article-title":"The Geriatric Nutritional Risk Index Predicts Long-Term Survival and Cardiovascular or Limb Events in Peripheral Arterial Disease","volume":"27","author":"Matsuo","year":"2020","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.amjcard.2009.12.054","article-title":"Comparison of Effects of Statin Use on Mortality in Patients with Peripheral Arterial Disease with versus without Elevated C-Reactive Protein and d-Dimer Levels","volume":"105","author":"Vidula","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Shah, A.J., Pavlatos, N., and Kalra, D.K. (2023). Preventive Therapies in Peripheral Arterial Disease. Biomedicines, 11.","DOI":"10.3390\/biomedicines11123157"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Belur, A.D., Shah, A.J., Virani, S.S., Vorla, M., and Kalra, D.K. (2022). Role of Lipid-Lowering Therapy in Peripheral Artery Disease. J. Clin. Med., 11.","DOI":"10.3390\/jcm11164872"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-Density Lipoprotein Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/2047487320902750","article-title":"LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial","volume":"28","author":"Sever","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5603\/AA.2019.0007","article-title":"The Position of Polish Experts on Conservative Management in Patients with Artery Diseases of Lower Limbs","volume":"25","author":"Krasinski","year":"2019","journal-title":"Acta Angiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jvs.2008.06.005","article-title":"The Association between Elevated Ankle Systolic Pressures and Peripheral Occlusive Arterial Disease in Diabetic and Nondiabetic Subjects","volume":"48","author":"Aboyans","year":"2008","journal-title":"J. Vasc. Surg."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"880","DOI":"10.33963\/KP.a2022.0155","article-title":"A New Approach of Statin Therapy in Carotid Atherosclerosis: Targeting Indices of Plaque Vulnerability on the Top of Lipid-Lowering. A Narrative Review","volume":"80","author":"Kadoglou","year":"2022","journal-title":"Kardiol. Pol."},{"key":"ref_86","first-page":"87","article-title":"Avoiding revascularization strategy versus revascularization with drug-coated balloon for the treatment of superficial femoral artery occlusive disease","volume":"4","author":"Ren","year":"2021","journal-title":"J. Interv. Med."},{"key":"ref_87","first-page":"465","article-title":"Severe, recurrent in-stent carotid restenosis: Endovascular approach, risk factors. Results from a prospective academic registry of 2637 consecutive carotid artery stenting procedures (TARGET-CAS)","volume":"15","author":"Tekieli","year":"2019","journal-title":"Post\u0119py Kardiol. Interw."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Nguyen, D.T., B\u00e9rczi, \u00c1., Ny\u00e1r\u00e1dy, B.B., Szonyi, \u00c1., Philippovich, M., and D\u00f3sa, E. (2022). Short- and Mid-Term Outcomes of Stenting in Patients with Isolated Distal Internal Carotid Artery Stenosis or Post-Surgical Restenosis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11195640"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1474-4422(10)70120-4","article-title":"Asymptomatic Embolisation for Prediction of Stroke in the Asymptomatic Carotid Emboli Study (ACES): A Prospective Observational Study","volume":"9","author":"Markus","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/0003-4819-123-9-199511010-00002","article-title":"Lack of Effect of Aspirin in Asymptomatic Patients with Carotid Bruits and Substantial Carotid Narrowing. The Asymptomatic Cervical Bruit Study Group","volume":"123","author":"Battista","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Antithrombotic Trialists\u2019 (ATT) Collaboration, Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., Buring, J., Hennekens, C., and Kearney, P. (2009). Aspirin in the Primary and Secondary Prevention of Vascular Disease: Collaborative Meta-Analysis of Individual Participant Data from Randomised Trials. Lancet, 373, 1849\u20131860.","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Canonico, M.E., Piccolo, R., Avvedimento, M., Leone, A., Esposito, S., Franzone, A., Giugliano, G., Gargiulo, G., Hess, C.N., and Berkowitz, S.D. (2023). Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10040164"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"121","DOI":"10.20452\/pamw.15215","article-title":"Aspirin for Primary Cardiovascular Prevention: Why the Wonder Drug Should Not Be Precipitously Dismissed","volume":"130","author":"Aimo","year":"2020","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejvs.2022.04.011","article-title":"Editor\u2019s Choice\u2014European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease","volume":"65","author":"Naylor","year":"2023","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1212\/WNL.0000000000001972","article-title":"Dual Antiplatelet Therapy in Stroke and ICAS: Subgroup Analysis of CHANCE","volume":"85","author":"Liu","year":"2015","journal-title":"Neurology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1161\/STROKEAHA.121.034089","article-title":"Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial","volume":"52","author":"Yaghi","year":"2021","journal-title":"Stroke"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s00270-023-03419-9","article-title":"Prediction of Bleeding by the PRECISE-DAPT Score in Patients with Carotid Artery Stenting","volume":"46","author":"Ramazanoglu","year":"2023","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1067\/mhj.2000.108239","article-title":"Reduction in the Need for Hospitalization for Recurrent Ischemic Events and Bleeding with Clopidogrel Instead of Aspirin. CAPRIE Investigators","volume":"140","author":"Bhatt","year":"2000","journal-title":"Am. Heart J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/ene.13695","article-title":"Efficacy and Safety of Dual Antiplatelet Therapy in the Elderly for Stroke Prevention: A Systematic Review and Meta-Analysis","volume":"25","author":"Ding","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.mayocp.2022.01.033","article-title":"Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients with Ischemic Stroke","volume":"97","author":"Huang","year":"2022","journal-title":"Mayo Clin. Proc."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index: A Randomized Controlled Trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"key":"ref_103","first-page":"e686","article-title":"2016 AHA\/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"135","author":"Gornik","year":"2017","journal-title":"Circulation"},{"key":"ref_104","first-page":"16566","article-title":"Who May Benefit from Low-Dose Rivaroxaban plus Aspirin? Practical Implications for Outpatients with Cardiovascular Disease","volume":"133","year":"2023","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without Aspirin in Patients with Stable Peripheral or Carotid Artery Disease: An International, Randomised, Double-Blind, Placebo-Controlled Trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"E181","DOI":"10.1093\/eurjpc\/zwab128","article-title":"Low-Dose Rivaroxaban and Aspirin among Patients with Peripheral Artery Disease: A Meta-Analysis of the COMPASS and VOYAGER Trials","volume":"29","author":"Anand","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s11239-020-02326-x","article-title":"Elderly People Are Inherently Sensitive to the Pharmacological Activity of Rivaroxaban: Implications for DOAC Prescribing","volume":"52","author":"Kampouraki","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_109","first-page":"16508","article-title":"Oral Anticoagulation Challenges and Therapeutic Dilemmas in the Very Elderly: To Treat and How to Treat Octogenarians and Nonagenarians?","volume":"133","author":"Papazoglou","year":"2023","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1161\/ATVBAHA.119.312142","article-title":"Evidence-Based Medical Management of Peripheral Artery Disease","volume":"40","author":"Bevan","year":"2020","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s43044-023-00402-0","article-title":"Is Triple Antithrombotic Therapy a Safe Option in Patients with AF Who Receive Drug-Eluting Stents?: A Review Article","volume":"75","author":"Alshahrani","year":"2023","journal-title":"Egypt. Heart J."},{"key":"ref_113","first-page":"303","article-title":"Triple Anticoagulation Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention\u2014Real Life Assessment","volume":"4","author":"Bogacki","year":"2016","journal-title":"Adv. Interv. Cardiol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5603\/AH.a2019.0008","article-title":"2019 Guidelines for the Management of Hypertension\u2014Part 1\u20137","volume":"23","author":"Tykarski","year":"2019","journal-title":"Arter. Hypertens."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"446","DOI":"10.33963\/KP.a2022.0297","article-title":"Risks Associated with Intensive Blood Pressure Control in Older Patients","volume":"81","author":"Rivasi","year":"2023","journal-title":"Kardiol. Pol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J. Hypertens."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/HYPERTENSIONAHA.120.14683","article-title":"Antihypertensive Treatment in Elderly Frail Patients: Evidence from a Large Italian Database","volume":"76","author":"Rea","year":"2020","journal-title":"Hypertension"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/eurjpc\/zwaa126","article-title":"Statin Treatment Reduces the Risk of Death among Elderly Frail Patients: Evidence from a Large Population-Based Cohort","volume":"28","author":"Rea","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Warwick, J., Falaschetti, E., Rockwood, K., Mitnitski, A., Thijs, L., Beckett, N., Bulpitt, C., and Peters, R. (2015). No Evidence That Frailty Modifies the Positive Impact of Antihypertensive Treatment in Very Elderly People: An Investigation of the Impact of Frailty upon Treatment Effect in the HYpertension in the Very Elderly Trial (HYVET) Study, a Double-Blind, Placebo-Controlled Study of Antihypertensives in People with Hypertension Aged 80 and Over. BMC Med., 13.","DOI":"10.1186\/s12916-015-0328-1"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ajh\/hpab145","article-title":"Is Medication Adherence Predictive of Cardiovascular Outcomes and Blood Pressure Control? The Systolic Blood Pressure Intervention Trial (SPRINT)","volume":"35","author":"Glasser","year":"2022","journal-title":"Am. J. Hypertens."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41440-018-0165-7","article-title":"Effects of Sartans and Low-Dose Statins on Cerebral White Matter Hyperintensities and Cognitive Function in Older Patients with Hypertension: A Randomized, Double-Blind and Placebo-Controlled Clinical Trial","volume":"42","author":"Zhang","year":"2019","journal-title":"Hypertens. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fnagi.2020.00154","article-title":"Telmisartan and Rosuvastatin Synergistically Ameliorate Dementia and Cognitive Impairment in Older Hypertensive Patients with Apolipoprotein E Genotype","volume":"12","author":"Hu","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1161\/STROKEAHA.115.011242","article-title":"Stroke Location Is an Independent Predictor of Cognitive Outcome","volume":"47","author":"Munsch","year":"2016","journal-title":"Stroke"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Smith, D., Lovell, J., Weller, C., Kennedy, B., Winbolt, M., Young, C., and Ibrahim, J. (2017). A systematic review of medication non-adherence in persons with dementia or cognitive impairment. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0170651"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Kang, W., and Pineda Hern\u00e1ndez, S. (2023). Understanding Cognitive Deficits in People with High Blood Pressure. J. Pers. Med., 13.","DOI":"10.3390\/jpm13111592"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1056\/NEJM199708213370802","article-title":"Cumulative Effects of High Cholesterol Levels, High Blood Pressure, and Cigarette Smoking on Carotid Stenosis","volume":"337","author":"Wilson","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/jgs.14834","article-title":"Determinants of Dropout and Nonadherence in a Dementia Prevention Randomized Controlled Trial: The Prevention of Dementia by Intensive Vascular Care Trial","volume":"65","author":"Beishuizen","year":"2017","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/ajh\/hpac128","article-title":"Blood Pressure Variability and Cognitive Decline: A Post Hoc Analysis of the SPRINT MIND Trial","volume":"36","author":"Sible","year":"2023","journal-title":"Am. J. Hypertens."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s11606-014-2947-1","article-title":"Characteristics and Long-Term Follow-up of Participants with Peripheral Arterial Disease during ALLHAT","volume":"29","author":"Piller","year":"2014","journal-title":"J. Gen. Intern. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"E006512","DOI":"10.1161\/CIRCOUTCOMES.120.006512","article-title":"Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID Trial","volume":"13","author":"Fudim","year":"2020","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3317\/jraas.2000.002","article-title":"The HOPE Study (Heart Outcomes Prevention Evaluation)","volume":"1","author":"Sleight","year":"2000","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1751-7141.2008.00010.x","article-title":"Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET): Implications for Reduced Cardiovascular Risk","volume":"12","author":"Liebson","year":"2009","journal-title":"Prev. Cardiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1161\/HYPERTENSIONAHA.110.169169","article-title":"\u03b2-Blockers in Patients with Intermittent Claudication and Arterial Hypertension: Results from the Nebivolol or Metoprolol in Arterial Occlusive Disease Trial","volume":"58","author":"Weisser","year":"2011","journal-title":"Hypertension"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/pds.932","article-title":"Antihypertensive Drug Therapy and the Risk of Lower Extremity Amputations in Pharmacologically Treated Type 2 Diabetes Patients","volume":"13","author":"Erkens","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_135","first-page":"266","article-title":"Value of Doppler ultrasonography in renal artery stenosis recognition","volume":"2","author":"Przewlocki","year":"2006","journal-title":"Post\u0119py Kardiol. Interw."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000534499","article-title":"Magnetic Resonance Imaging in Atherosclerotic Renal Artery Stenosis: The Update and Future Directions from Interventional Perspective","volume":"10","author":"Fu","year":"2024","journal-title":"Kidney Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jfma.2021.01.007","article-title":"Gadolinium-Enhanced Magnetic Resonance versus Computed Tomography Angiography for Renal Artery Stenosis: A Systematic Review and Meta-Analysis","volume":"120","author":"Wang","year":"2021","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/ndt\/gfr496","article-title":"Dispelling the Myth: The Use of Renin-Angiotensin Blockade in Atheromatous Renovascular Disease","volume":"27","author":"Chrysochou","year":"2012","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/ndt\/gfh865","article-title":"Long-Term Follow-up of Atherosclerotic Renovascular Disease. Beneficial effect of ACE inhibition","volume":"20","author":"Losito","year":"2005","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ahj.2008.05.013","article-title":"Angiotensin Inhibition in Renovascular Disease: A Population-Based Cohort Study","volume":"156","author":"Hackam","year":"2008","journal-title":"Am. Heart J."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e12474","DOI":"10.1111\/1755-5922.12474","article-title":"Calcium Channel Blockers Are Associated with Improved Survival and Lower Cardiovascular Mortality in Patients with Renovascular Disease","volume":"306","author":"Deshmukh","year":"2018","journal-title":"Cardiovasc. Ther."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jash.2015.12.002","article-title":"Associations of Antiplatelet Therapy and Beta Blockade with Patient Outcomes in Atherosclerotic Renovascular Disease","volume":"10","author":"Ritchie","year":"2016","journal-title":"J. Am. Soc. Hypertens."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Badacz, R., Kab\u0142ak-Ziembicka, A., Ros\u0142awiecka, A., Rze\u017anik, D., Baran, J., Trystu\u0142a, M., Legutko, J., and Przew\u0142ocki, T. (2022). The Maintained Glycemic Target Goal and Renal Function Are Associated with Cardiovascular and Renal Outcomes in Diabetic Patients Following Stent-Supported Angioplasty for Renovascular Atherosclerotic Disease. J. Pers. Med., 12.","DOI":"10.3390\/jpm12040537"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2337\/dc23-0492","article-title":"Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients with Type 2 Diabetes","volume":"46","author":"Moura","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"589","DOI":"10.5603\/EP.a2021.0098","article-title":"Flozins\u2014In the Light of the Latest Recommendations","volume":"72","author":"Rokicka","year":"2021","journal-title":"Endokrynol. Pol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41574-021-00512-2","article-title":"Type 2 Diabetes Mellitus in Older Adults: Clinical Considerations and Management","volume":"17","author":"Bellary","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2021). 6. Glycemic targets: Standards of medical care in diabetes-2021. Diabetes Care, 44, S73\u2013S84.","DOI":"10.2337\/dc21-S006"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1161\/CIR.0000000000000920","article-title":"Cardiorenal Protection with the Newer Antidiabetic Agents in Patients with Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association","volume":"142","author":"Rangaswami","year":"2020","journal-title":"Circulation"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ejhf.1673","article-title":"European Society of Cardiology\/Heart Failure Association Position Paper on the Role and Safety of New Glucose-Lowering Drugs in Patients with Heart Failure","volume":"22","author":"Coats","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2054358120935701","DOI":"10.1177\/2054358120935701","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review","volume":"7","author":"Dubrofsky","year":"2020","journal-title":"Can. J. Kidney Health Dis."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: A systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/ckj\/sfz170","article-title":"The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: No longer a cause of concern?","volume":"13","author":"Sarafidis","year":"2019","journal-title":"Clin. Kidney J."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/ATVBAHA.123.319156","article-title":"Presence of Peripheral Artery Disease Is Associated with Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled","volume":"43","author":"Verma","year":"2023","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"30","DOI":"10.15277\/bjd.2021.292","article-title":"A Systematic Review and Meta-Analysis of the Impact of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on Cardiovascular Outcomes in Biologically Healthy Older Adults","volume":"21","author":"Strain","year":"2021","journal-title":"Br. J. Diabetes"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12933-016-0356-y","article-title":"Cardiovascular Effects of Dapagliflozin in Patients with Type 2 Diabetes and Different Risk Categories: A Meta-Analysis","volume":"15","author":"Sonesson","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/ageing\/afz096","article-title":"Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME trial","volume":"48","author":"Monteiro","year":"2019","journal-title":"Age Ageing"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus and Previous Myocardial Infarction","volume":"139","author":"Furtado","year":"2019","journal-title":"Circulation"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s13300-021-01035-9","article-title":"Diabetes and Frailty: An Expert Consensus Statement on the Management of Older Adults with Type 2 Diabetes","volume":"12","author":"Strain","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"m2812","DOI":"10.1136\/bmj.m2812","article-title":"Risk of Amputation with Canagliflozin across Categories of Age and Cardiovascular Risk in Three US Nationwide Databases: Cohort Study","volume":"370","author":"Fralick","year":"2020","journal-title":"BMJ"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes: Results from the CANVAS Program Randomised Clinical Trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"afac201","DOI":"10.1093\/ageing\/afac201","article-title":"The Role of Sodium-Glucose Co-Transporter-2 Inhibitors in Frail Older Adults with or without Type 2 Diabetes Mellitus","volume":"51","author":"Evans","year":"2022","journal-title":"Age Ageing"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3390\/endocrines4030045","article-title":"Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect\u2014What Is New in 2023?","volume":"4","author":"Young","year":"2023","journal-title":"Endocrines"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/dom.14671","article-title":"Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial","volume":"24","author":"Barraclough","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/pdi.2051","article-title":"SUSTAIN-6: Cardiovascular Safety of a Once-Weekly GLP-1 Receptor Agonist","volume":"33","author":"Cordiner","year":"2016","journal-title":"Pract. Diabetes"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"110799","DOI":"10.1016\/j.diabres.2023.110799","article-title":"Glucagon-like peptide-1 treatment reduces the risk of diabetes-type 2 related amputations: A cohort study in Denmark","volume":"202","author":"Mathisen","year":"2023","journal-title":"Diab. Res. Clin. Prac."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium Glucose Cotransporter 2 Inhibitors and Risk of Serious Adverse Events: Nationwide Register Based Cohort Study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"154343","DOI":"10.1016\/j.metabol.2020.154343","article-title":"Cardiovascular outcomes trials with incretin-based medications: A critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors","volume":"111","author":"Sachinidis","year":"2020","journal-title":"Metabolism"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/dc18-1094","article-title":"The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients with Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial","volume":"41","author":"Dhatariya","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"101325","DOI":"10.1016\/j.diabet.2022.101325","article-title":"Lower limb amputations: Protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?","volume":"48","author":"Scheen","year":"2022","journal-title":"Diabetes Metab."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"108390","DOI":"10.1016\/j.jdiacomp.2022.108390","article-title":"Impact of Glucagon-like Peptide 1 Receptor Agonists on Peripheral Arterial Disease in People with Diabetes Mellitus: A Narrative Review","volume":"37","author":"Liarakos","year":"2023","journal-title":"J. Diabetes Complicat."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cea.12860","article-title":"Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation","volume":"47","author":"Mitchell","year":"2017","journal-title":"Clin. Exp. Allergy"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(19)32131-2","article-title":"Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): A 5-year, multicentre, randomised, double-blind trial","volume":"394","author":"Matthews","year":"2019","journal-title":"Lancet"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Noguchi, Y., Yoshizawa, S., Tachi, T., and Teramachi, H. (2022). Effect of Dipeptidyl Peptidase-4 Inhibitors vs. Metformin on Major Cardiovascular Events Using Spontaneous Reporting System and Real-World Database Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11174988"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2337\/dc16-1135","article-title":"Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)","volume":"40","author":"Bethel","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2337\/dc14-2868","article-title":"Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial","volume":"38","author":"Leiter","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1475-2840-11-3","article-title":"Cardiovascular Safety with Linagliptin in Patients with Type 2 Diabetes Mellitus: A Pre-Specified, Prospective, and Adjudicated Meta-Analysis of a Phase 3 Programme","volume":"11","author":"Johansen","year":"2012","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.amjmed.2016.10.016","article-title":"Dipeptidyl peptidase-4 inhibitors, peripheral arterial disease, and lower extremity amputation risk in diabetic patients","volume":"130","author":"Chang","year":"2017","journal-title":"Am. J. Med."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.jdiacomp.2016.07.027","article-title":"Hypoglycemia, frailty and dementia in older people with diabetes: Reciprocal relations and clinical implications","volume":"30","author":"Abdelhafiz","year":"2016","journal-title":"J. Diabetes Complicat."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Muszalik, M., St\u0119pie\u0144, H., Puto, G., Cybulski, M., and Kurpas, D. (2022). Implications of the Metabolic Control of Diabetes in Patients with Frailty Syndrome. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph191610327"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Lu, H., Lu, H., Kosinski, C., Wojtusciszyn, A., Zanchi, A., Carron, P.-N., M\u00fcller, M., Meyer, P., Martin, J., and Muller, O. (2021). SGLT2 Inhibitors, What the Emergency Physician Needs to Know: A Narrative Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10092036"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e1128","DOI":"10.1097\/MD.0000000000001128","article-title":"Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study","volume":"94","author":"Chen","year":"2015","journal-title":"Medicine"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1161\/CIRCULATIONAHA.115.015511","article-title":"Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial","volume":"132","author":"Scirica","year":"2015","journal-title":"Circulation"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Lisowska, A., Dubat\u00f3wka, M., Chlabicz, M., Jamio\u0142kowski, J., Kondraciuk, M., Szyszkowska, A., Knapp, M., Szpakowicz, A., \u0141ukasiewicz, A., and Kami\u0144ski, K. (2023). Disparities in the Prevalence and Risk Factors for Carotid and Lower Extremities Atherosclerosis in a General Population\u2014Bialystok PLUS Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072627"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Badacz, R., Przew\u0142ocki, T., Pienia\u017cek, P., Ros\u0142awiecka, A., Kleczy\u0144ski, P., Legutko, J., \u017bmudka, K., and Kab\u0142ak-Ziembicka, A. (2022). MicroRNA-134-5p and the Extent of Arterial Occlusive Disease Are Associated with Risk of Future Adverse Cardiac and Cerebral Events in Diabetic Patients Undergoing Carotid Artery Stenting for Symptomatic Carotid Artery Disease. Molecules, 27.","DOI":"10.3390\/molecules27082472"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.apmr.2007.11.005","article-title":"Estimating the Prevalence of Limb Loss in the United States: 2005 to 2050","volume":"89","author":"MacKenzie","year":"2008","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Schott, G., Martinez, Y.V., Ediriweera De Silva, R.E., Renom-Guiteras, A., V\u00f6gele, A., Reeves, D., Kunnamo, I., Marttila-Vaara, M., and S\u00f6nnichsen, A. (2017). Effectiveness and Safety of Dipeptidyl Peptidase 4 Inhibitors in the Management of Type 2 Diabetes in Older Adults: A Systematic Review and Development of Recommendations to Reduce Inappropriate Prescribing. BMC Geriatr., 17.","DOI":"10.1186\/s12877-017-0571-8"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s13300-017-0360-6","article-title":"Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database","volume":"9","author":"Wang","year":"2018","journal-title":"Diabetes Ther."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"100054","DOI":"10.1016\/j.deman.2022.100054","article-title":"Lower-Limb Amputations in Patients Treated with SGLT2 Inhibitors versus DPP-4 Inhibitors: A Meta-Analysis of Observational Studies","volume":"6","author":"Scheen","year":"2022","journal-title":"Diabetes Epidemiol. Manag."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.amjcard.2018.09.014","article-title":"Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients with Diabetes Mellitus (From the SAVOR-TIMI 53 Trial)","volume":"123","author":"Gutierrez","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Cavallari, G., and Mancini, E. (2022). The Nephrologist\u2019s Role in the Collaborative Multi-Specialist Network Taking Care of Patients with Diabetes on Maintenance Hemodialysis: An Overview. J. Clin. Med., 11.","DOI":"10.3390\/jcm11061521"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Wachsmann-Maga, A., Maga, M., Polczyk, R., W\u0142odarczyk, A., Pasieka, P., Terlecki, K., and Maga, P. (2023). Vascular Inflammatory Markers as Predictors of Peripheral Arterial Disease Patients\u2019 Quality-of-Life Changes after Endovascular Treatment. J. Clin. Med., 12.","DOI":"10.3390\/jcm12103412"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Badacz, R., Kleczy\u0144ski, P., Legutko, J., \u017bmudka, K., Gaco\u0144, J., Przew\u0142ocki, T., and Kab\u0142ak-Ziembicka, A. (2021). Expression of miR-1-3p, miR-16-5p and miR-122-5p as Possible Risk Factors of Secondary Cardiovascular Events. Biomedicines, 9.","DOI":"10.3390\/biomedicines9081055"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"2304667","DOI":"10.1080\/07853890.2024.2304667","article-title":"The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis","volume":"55","author":"Stachteas","year":"2023","journal-title":"Ann. Med."},{"key":"ref_199","first-page":"677","article-title":"Microparticles, not only markers but also a therapeutic target in the early stage of diabetic retinopathy and vascular aging","volume":"16","author":"Stepien","year":"2012","journal-title":"Med. Sci. Monit."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Theofilis, P., Sagris, M., Oikonomou, E., Antonopoulos, A.S., Siasos, G., Tsioufis, K., and Tousoulis, D. (2022). The Anti-Inflammatory Effect of Novel Antidiabetic Agents. Life, 12.","DOI":"10.3390\/life12111829"},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Cecchini, A.L., Biscetti, F., Manzato, M., Lo Sasso, L., Rando, M.M., Nicolazzi, M.A., Rossini, E., Eraso, L.H., Dimuzio, P.J., and Massetti, M. (2023). Current Medical Therapy and Revascularization in Peripheral Artery Disease of the Lower Limbs: Impacts on Subclinical Chronic Inflammation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216099"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1479164117733626","article-title":"Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis","volume":"15","author":"Gaspari","year":"2018","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Sagris, M., Theofilis, P., Antonopoulos, A.S., Tsioufis, K., and Tousoulis, D. (2022). Telomere Length: A Cardiovascular Biomarker and a Novel Therapeutic Target. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232416010"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"109825","DOI":"10.1016\/j.cellsig.2020.109825","article-title":"The SGLT2 inhibitor empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2\/ROS\/NLRP3\/caspase-1-dependent IL-1\u03b2 and IL-18 secretion","volume":"77","author":"Sukhanov","year":"2021","journal-title":"Cell Signal."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Pignatelli, P., Baratta, F., Buzzetti, R., D\u2019amico, A., Castellani, V., Bartimoccia, S., Siena, A., D\u2019onofrio, L., Maddaloni, E., and Pingitore, A. (2022). The sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce platelet activation and thrombus formation by lowering NOX2-Related oxidative stress: A pilot study. Antioxidants, 11.","DOI":"10.3390\/antiox11101878"},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Durante, W., Behnammanesh, G., and Peyton, K.J. (2021). Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168786"},{"key":"ref_208","first-page":"74","article-title":"Empagliflozin may regresses carotid intima-media thickness and epicardial adipose tissue volume in patients with type 2 diabetes mellitus","volume":"1","author":"Ardahanli","year":"2021","journal-title":"Lokman Hekim Health Sci."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/postgradmedj-2019-137186","article-title":"An overview of GLP-1 agonists and recent cardiovascular outcomes trials","volume":"96","author":"Sheahan","year":"2020","journal-title":"Postgrad. Med. J."},{"key":"ref_210","first-page":"379","article-title":"Underutilization of guideline-recommended therapy in patients 80 years and older with peripheral artery diseases","volume":"52","author":"Messiha","year":"2023","journal-title":"Vasa"},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Wawruch, M., Murin, J., Tesar, T., Paduchova, M., Petrova, M., Celovska, D., Havelkova, B., Trnka, M., and Aarnio, E. (2021). Reinitiation and Subsequent Discontinuation of Antiplatelet Treatment in Nonpersistent Older Patients with Peripheral Arterial Disease. Biomedicines, 9.","DOI":"10.3390\/biomedicines9091280"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/5\/1508\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:09:43Z","timestamp":1760105383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/5\/1508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":211,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["jcm13051508"],"URL":"https:\/\/doi.org\/10.3390\/jcm13051508","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]}}}